Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

Documenti analoghi

• Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed‐Dose Titration of Weekly Insulin Efsitora in Insulin‐Naïve Type 2 Diabetes
  di: Lisa Connery, et al.
  Pubblicazione: (2026)
• Comparison of Glucose Management Between Open‐Source Loop and Tandem Control‐ IQ Automated Insulin Delivery Systems in Adults With Type 1 Diabetes
  di: Zekai Wu, et al.
  Pubblicazione: (2026)
• Clinical Outcomes With Once‐Weekly Insulin Icodec Versus Once‐Daily Insulin Glargine U100 in Insulin‐Naïve and Previously Insulin‐Treated Individuals With Type 2 Diabetes: A Meta‐Analysis of Randomised Controlled Trials
  di: Mushood Ahmed, et al.
  Pubblicazione: (2024)
• Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes ( ONWARDS 10): A Randomised Controlled Trial
  di: Julio Rosenstock, et al.
  Pubblicazione: (2026)
• The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus
  di: Geremia B. Bolli, et al.
  Pubblicazione: (2026)